Ongoing selection for a uniquely human null allele of SIGLEC12 in world-wide populations may protect against the risk of advanced carcinomas

FASEB Bioadv. 2021 Mar 30;3(4):278-279. doi: 10.1096/fba.2021-00036. eCollection 2021 Apr.
No abstract available